Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Farmeconomia. Health economics and therapeutic pathways
429 Publications
collected from a compatible aggregator


  • Personalized medicine: biomarkers and companion diagnostics

    Bernardini, Renato; Gancitano, Giovanni; Balice, Angela; Di Mauro, Rosaria; Cantarella, Giuseppina; Dionisi, Matteo (2018)
    Great expectations are bound to the current evolution of medicine to personalized medicine. Thanks to rapid advances in genomics and molecular biology, new markers can be revealed for the presence of or susceptibility to a disease, or response to treatment. On such markers, diagnostic tests can be based; companion diagnostics (CDx, often called In Vitro devices) are diagnostic tests “coupled” with a therapeutic drug, aimed at assessing its applicability to a specific class of patients. As wel...

    Albutrepenonacog alfa (Idelvion®) for the treatment of Italian patients with hemophilia B: a budget impact model

    Pradelli, Lorenzo; Villa, Sara; Castaman, Giancarlo (2018)
    BACKGROUND: Enhanced pharmacokinetic profile of albutrepenonacog alfa allows to prolong the interdose period in prophylaxis, maintaining higher trough level, and to reduce dosage needed for bleeding. This improvement could lead to a better efficiency of the hemophilia B treatment.OBJECTIVES: To estimate the impact of this new drug on the Italian National Health System (NHS).METHODS: A model was developed from the NHS perspective to assess the budget impact of treating severe hemophilia B with...

    Estimating the cost-effectiveness of treatment for prevention of thromboembolic events in at-risk adults with non-valvular atrial fibrillation

    Bellone, Marco; Pradelli, Lorenzo; Bo, Mario (2018)
    INTRODUCTION: The direct oral anticoagulants (DOACs) have demonstrated a more predictable effect and a more favorable risk-benefit ratio compared to the standard oral anticoagulant treatment for the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF).AIM: To estimate the efficiency of DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban vs. warfarin), in the prevention of clinical events in adult patients with NVAF.METHODS: A deterministic incremental cost-effectiv...

    [Tecfidera® (delayed-release dimethylfumarate) in the treatment of relapsing-remitting multiple sclerosis]

    Mantovani, Lorenzo Giovanni; Furneri, Gianluca; Cortesi, Paolo Angelo; Amato, Maria Pia; Caputi, Achille Patrizio; Piacentini, Patrizio; Solari, Alessandra; Pozzilli, Carlo; Comi, Giancarlo (2017)
    The present health technology assessment (HTA) evaluates the clinical and economic profile of delayed-release dimethylfumarate (DMF, also known as gastro-resistant DMF) in the treatment of relapsing-remitting multiple sclerosis (RRMS) in Italy. Chapter 1 briefly introduces the condition (multiple sclerosis and, more specifically, the relapsing-remitting form) and provides an overall description of the main therapeutic options for physicians, in terms of clinical evidence, regulatory status in...

    Economic implications in inflammatory bowel disease: results from a retrospective analysis in an Italian Centre

    Variola, Angela; Massella, Arianna; Geccherle, Andrea; Bocus, Paolo; Tessari, Roberto; Zuppini, Teresa; Ravasio, Roberto (2017)
    BACKGROUND: Inflammatory bowel disease (IBD) represents a group of chronic conditions characterized by elevated costs. Over the last years, also a considerable healthcare burden associated with IBD has emerged, due to an increasing use of biological drugs and hospitalization costs. Despite the creation of local or regional databases, data regarding healthcare expenditure are lacking in Italy.AIM: To evaluate the treatment cost (biological drugs and hospitalizations) for patients with ulcerati...
  • No data provider research data found
  • Latest Documents Timeline

    Chart is loading... It may take a bit of time. Please be patient and don't reload the page.

    Document Types

    Chart is loading... It may take a bit of time. Please be patient and don't reload the page.

Share - Bookmark